基于非靶向代谢组学的冠突散囊菌发酵代谢产物分析

Analysis of the Fermentation Metabolites from Eurotium cristatum Basedon the Non-targeted Metabolomics

冠突散囊菌在降糖降脂功能性食品和天然药物的开发中具有重要的应用价值。分析冠突散囊菌整体代谢产物信息和产生的降糖降脂活性成分,可以为菌株的开发和应用提供理论基础和数据支持。以冠突散囊菌菌株Ys-Ec-01为试验材料,采用基于超高效液相色谱-四级杆静电场轨道阱质谱(UHPLC-QE-MS)技术的非靶向代谢组学,结合主成分分析(PCA)和正交偏最小二乘法-判别分析(OPLS-DA)方法,分析Ys-Ec-01发酵代谢产物谱,寻找降糖降脂活性产物。结果表明:Ys-Ec-01发酵后代谢产物谱发生显著变化。从代谢产物谱中,鉴定出365种发酵产物,进而筛选出205种差异发酵产物和151种主要发酵产物,鉴定到13种降糖降脂活性成分,分别是金圣草黄素、山奈酚、异鼠李素、表儿茶素、辣椒素酯、烟酸、葫芦巴碱、1-脱氧野尻霉素、尿囊素、原儿茶酸、亚油酸、胆碱和L肉碱。这些活性成分为Ys-Ec-01的降糖降脂功能研究和开发应用提供更多靶点和基本信息。

Eurotium cristatum had important application value in the development of hypoglycemic and lipid-lowering functional foods and natural medicines.The analysis of the overall metabolite information and the hypoglycemic and lipid-lowering active ingredients produced by Eurotium cristatum could provide theoretical basis and data support for the development and application of the bacterial strain.By taking the strain Ys-Ec-01 of Eurotium cristatum as the experimental material,the non-targeted metabolomics based on the ultra performance liquid chromatography-quadrupole electrostatic field orbitrap mass spectrometry(UHPLC-QE-MS)technology was used to analyze the fermentation metabolic profile Ys-Ec-01 by combining with the principal component analysis(PCA)and the orthogonal partial least squares-discriminant analysis(OPLS-DA),in order to find the hypoglycemic and lipid-lowering active products.The results showed that the metabolite profile of Ys-Ec-01 changed significantly after the fermentation.From the metabolite profile,a total of 365 fermentation products were identified,and then 205 differential fermentation products and 151 main fermentation products were screened,thus to identify 13 hypoglycemic and lipid-lowering active ingredients,which were chrysoeriol,kaempferol,isorhamnetin,epicatechin,capsaicin,nicotinic acid,trigonelline,1-deoxynojirimycin,allantoin,protocatechuic acid,linoleic acid,choline and L-carnitine.These active ingredients provided more targets and basic information for the research,development and application of hypoglycemic and lipid-lowering function of Ys-Ec-01.